Brace Pharma Capital: Funding, Team & Investors | Startup Intros

Loading organizations...

Brace Pharma Capital: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Nov 1, 2021	Antiva Biosciences	$31.0M Series D	Adjuvant Capital	Canaan Partners, Johnson & Johnson Innovation, Osage University Partners, Alexandria Venture Investments, Avestria Ventures, Canaan Partners, Dong-A ST, Gaingels, Google Ventures, HBM Healthcare Investments, Lumira Ventures, Mana Ventures, Sirona Capital, Sofinnova Ventures
Jul 1, 2021	Turnstone Biologics	$80.0M Series D	Santhosh Palani, PhD, CFA, Point72	KohFounders, Sofinnova Investments, venBio, Venrock, Versant Ventures, 404 Bio, CaaS Capital Management, Eventide Asset Management, F-Prime Capital, JM Family Enterprises, Northleaf Capital Partners, OrbiMed, Ridgeback Capital Investments, Sectoral Asset Management, Sixty Degree Capital, Surveyor Capital, Takeda Ventures, Teralys Capital
Aug 1, 2020	ReViral	$44.0M Series C	Jason Zhou	Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, Perceptive Advisors
May 1, 2020	HotSpot Therapeutics	$65.0M Series B	SR One	AbbVie Ventures, Access Biotechnology, Atlas Venture, Novo Ventures, RiverVest, Roche Venture Fund, Soffinova Partners, MRL Ventures Fund, Solasta Ventures, Henry Skinner
Nov 13, 2019	Avidity Biosciences	$100.0M Series C	Roderick Wong	Alethea Capital, Alexandria Venture Investments, Boxer Capital, Cormorant Asset Management, CureDuchenne Ventures, EcoR1 Capital, Eli Lilly and Company, Logos Capital, Partner Fund Management, Perceptive Advisors, ST Pharm, Takeda Ventures
Jul 1, 2018	ReViral	$55.0M Series B	Isaac Manke, Nanna Lüneborg	Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston, Perceptive Advisors
Jul 1, 2018	Antiva Biosciences	$15.0M Series C	Hillhouse Capital Group	Canaan Partners, Johnson & Johnson Innovation, Osage University Partners, Canaan Partners, Lumira Ventures, Sirona Capital, Sofinnova Ventures
Jan 1, 2018	Avrobio	$60.0M Series B	Cormorant Asset Management, Surveyor Capital	Atlas Venture, Endeavor Venture Funds, Ben Robbins, Hatteras Venture Partners, Aisling Capital, Clarus Ventures, Eventide Asset Management, Morningside, SV Health Investors
Mar 1, 2017	Antiva Biosciences	$22.0M Series C	Vinzenz Ploerer	Canaan Partners, Johnson & Johnson Innovation, Osage University Partners, Alexandria Venture Investments, Canaan Partners, NS Investment, Sofinnova Ventures
Jan 1, 2017	Avidity Biosciences	$16.0M Series B	Michael Martin	F-Prime Capital Partners, Tony Hsu, Alexandria Venture Investments, Todd Brady, EcoR1 Capital, F-Prime Capital, Moore Venture Partners, Tavistock Group
Jan 1, 2016	Zymeworks	$62.0M Series A	BDC Venture Capital, Daniel Hétu	Amplitude VC, MPM Capital, Relay Ventures, Venrock, Anthony Lacavera, Celgene, CTI Life Sciences Fund, Eli Lilly and Company, Merlin Nexus, Northleaf Capital Partners, Perceptive Advisors, Teralys Capital
Dec 1, 2015	Navitor Pharmaceuticals	$33.0M Series B	Vinzenz Ploerer	Endeavor Venture Funds, Polaris Partners, Venrock, Atlas Venture, Johnson & Johnson Innovation, Polaris Partners, Barry Burgdorf, Sanofi Ventures, SR One
Nov 9, 2015	Therabron	$6.8M Series B Extension	Brace Pharma Capital	—
Nov 1, 2015	Viridian Therapeutics	$41.0M Series C	Jafco Ventures, Joshua Resnick	Atlas Venture, MPM Capital, Amgen Ventures, Boulder Ventures, MP Healthcare Venture Management, Remeditex Ventures
Jun 1, 2015	Cogent Biosciences	$65.0M Series B	Liam Ratcliffe	Access Biotechnology, Atlas Venture, Brandon Capital Partners, Josh Resnick, Cowen Private Investments, F-Prime Capital, Jennison Associates, Novo Holdings, Sabby Management, Sanofi Ventures, Seattle Genetics, Sectoral Asset Management, Wellington Management
Dec 18, 2014	Therabron	$11.1M Series B	—	Vinzenz Ploerer, Zell Biotech Two
Jun 19, 2014	Tyrogenex	$15.0M Series D	Vinzenz Ploerer	—